<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925818</url>
  </required_header>
  <id_info>
    <org_study_id>2358/CE</org_study_id>
    <nct_id>NCT03925818</nct_id>
  </id_info>
  <brief_title>Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication</brief_title>
  <acronym>LactoBismu</acronym>
  <official_title>Twice-a-day PPI, Tetracycline, Metronidazolequadruple Therapy With Pylera® or Lactobacillus Reuteri for Treatment naïve or for Retreatment of H. Pylori: Two Randomized Pilot Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Sassari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Sassari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy of a b.i.d. quadruple therapy containing Pylera® or L.
      reuteri for H. pylori infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bismuth, metronidazole and tetracycline yielded high cure rates for H. pylori infection.
      Earlier studies suggested that the bismuth quadruple therapy may be effective when given
      twice-a-day rather than q.i.d. and that b.i.d. therapy was associated with fewer side
      effects. The addition of the probiotic Lactobacillus reuteri (Gastrus®) to Lactobacillus
      reuteri (Gastrus®) that has been shown to increase the cure rates by 10-14%. In another study
      bismuth supplementation with L. reuteri DSM 17938, in a modified low dose quadruple therapy
      provided good eradication rates (93.3%; 95% CI : 85-99%) in clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lactobacillus reuteri (Gastrus®) was not anymore available in the region
  </why_stopped>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">December 23, 2018</completion_date>
  <primary_completion_date type="Actual">November 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>30-40 days after the end of treatment</time_frame>
    <description>a negative 13C-urea breath test and/or a negative stool antigen test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance and side effects evaluation</measure>
    <time_frame>30-40 days</time_frame>
    <description>Patient interview at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>B.I.D. TMPPI + Lactobacillus-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B.I.D. Bismuth</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Subcitrate Potassium</intervention_name>
    <description>Pylera capsules</description>
    <arm_group_label>B.I.D. TMPPI + Lactobacillus-10</arm_group_label>
    <other_name>Pylera</other_name>
    <other_name>Metronidazole, Tetracycline, pantoprazole, Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gastrus</intervention_name>
    <description>Gastrus 1 tablet</description>
    <arm_group_label>B.I.D. Bismuth</arm_group_label>
    <other_name>L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Positive for H. pylori infection

        Exclusion Criteria:

          -  Presence of malignancy

          -  Pregnancy or lactation

          -  Clinically significant diseases

          -  History of drug or alcohol abuse

          -  Allergy to pantoprazole or to any component of regimens used in the study

          -  Use of anti-secretory drugs, antibiotics or probiotics 4 weeks preceding the
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIA P Dore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Sassari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Sassari</investigator_affiliation>
    <investigator_full_name>Maria Pina Dore</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus reuteri; Bismuth; Helicobacter pylori;</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

